NSRX · Nasus Pharma Ltd
United States · RS rating 36 · As of 2026-11-03
| Price | 3.20 USD |
|---|---|
| 1-day change | +0.0% |
| RS rating (overall / 1M / 3M / 12M) | 36 / 25 / 59 / 17 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 21 / 16 / 17 |
| Industry group (rank) | Medical-Ethical Drugs (94) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | – |
| Distance from 52-week high | +65.0% |
| Market cap (USD) | $39.8M |